These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38403514)

  • 21. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
    Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
    Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
    Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A
    Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
    Manfredi S; Turpin A; Malka D; Barbier E; Laurent-Puig P; Zaanan A; Dahan L; Lièvre A; Phelip JM; Michel P; Hautefeuille V; Legoux JL; Lepage C; Tougeron D; Aparicio T
    Dig Liver Dis; 2020 Oct; 52(10):1143-1147. PubMed ID: 32747302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS).
    Decoster L; Kenis C; Naessens B; Houbier G; De Man M; Lambrecht G; Monsaert E; Moons V; Vergauwe P; Prenen H; Van Cutsem E; Wildiers H
    J Geriatr Oncol; 2018 Mar; 9(2):93-101. PubMed ID: 29133190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
    Abraham JP; Magee D; Cremolini C; Antoniotti C; Halbert DD; Xiu J; Stafford P; Berry DA; Oberley MJ; Shields AF; Marshall JL; Salem ME; Falcone A; Grothey A; Hall MJ; Venook AP; Lenz HJ; Helmstetter A; Korn WM; Spetzler DB
    Clin Cancer Res; 2021 Feb; 27(4):1174-1183. PubMed ID: 33293373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
    Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
    Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
    van Nassau SC; Bond MJ; Scheerman I; van Breeschoten J; Kessels R; Valkenburg-van Iersel LB; Verheul HM; Buffart TE; Mekenkamp LJ; Lemmens VE; Koopman M; Bol GM;
    JAMA Netw Open; 2021 Sep; 4(9):e2124766. PubMed ID: 34505885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.
    Artaç M; Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2019 Jun; 50(2):214-220. PubMed ID: 29302856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
    Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J
    Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
    Cremolini C; Marmorino F; Bergamo F; Aprile G; Salvatore L; Masi G; Dell'Aquila E; Antoniotti C; Murgioni S; Allegrini G; Borelli B; Gemma D; Casagrande M; Granetto C; Delfanti S; Di Donato S; Schirripa M; Sensi E; Tonini G; Lonardi S; Fontanini G; Boni L; Falcone A
    Eur J Cancer; 2019 Mar; 109():175-182. PubMed ID: 30735919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study.
    Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Lan YT; Lin CC; Yen CC; Tzeng CH; Teng HW
    J Cancer Res Clin Oncol; 2014 Nov; 140(11):1927-36. PubMed ID: 24934725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
    Elshenawy MA; Badran A; Aljubran A; Alzahrani A; Rauf MS; Eldali A; Bazarbashi S
    World J Surg Oncol; 2020 Jul; 18(1):163. PubMed ID: 32641137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.